Multi-platinum Singer and Songwriter Ally Brooke Hernandez Shares her Migraine Journey to Help the Latino Community Living with Disease

(BPT) – Content sponsored and provided by Pfizer. Ally Brooke Hernandez has partnered with Pfizer to share her experience living with migraine.For Ally Brooke Hernandez — a singer and songwriter who first rose to fame in 2012 while she was a member of a successful singing group — migraine has been a part of her life since she was 11 years old. The debilitating disease, which causes symptoms including pulsating headaches that can be associated with nausea or vomiting and sensitivity to sound and/or light, affects nearly 40 million people in the U.S. However, Latinos with headaches are 50% less likely to receive a migraine diagnosis than non-Latino white patients.1“When I learned about the disparity of migraine diagnosis rates between Latino adults and non-Latino white adults, I knew I needed to share my story in an effort to make a difference for my community,” said Ally. “Living with migraine has been extremely debilitating and unbearable for me. Family is very important in our culture and spending time with my loved ones is one of my favorite things to do. Unfortunately, I have had to miss out on countless gatherings due to migraine attacks. It is devastating.”Along with her personal life, migraine also impacted her career. Her attacks forced her to miss recording sessions and other commitments. Before a concert, with thousands waiting to see and hear her perform, Ally used to worry that at the slightest hint of an oncoming migraine, she’d have to cancel her show. Once, she was in Miami for a festival performance and felt a migraine attack coming on from the stress of the show. She was forced to push through it and perform with a migraine because she didn’t want to let her fans down.With the help of her physician, Ally has found a treatment that can work for her. She takes Nurtec® ODT (rimegepant) as an acute treatment but it is approved to treat migraine and prevent episodic migraine in adults.“I want the Latino community to know that there is hope for migraine,” said Ally. “You may not have to live with this debilitating disease impacting many aspects of your life — be an advocate for yourself and go to the doctor if you are struggling.”Visit Nurtec.com for more information.IndicationsNURTEC ODT orally disintegrating tablets is a prescription medicine that is used to treat migraine in adults. It is for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine. It is not known if NURTEC ODT is safe and effective in children.IMPORTANT SAFETY INFORMATIONDo not take Nurtec ODT if you are allergic to Nurtec ODT (rimegepant) or any of its ingredients.Before you take Nurtec ODT, tell your healthcare provider (HCP) about all your medical conditions, including if you:have liver problems,have kidney problems,are pregnant or plan to become pregnant,are breastfeeding or plan to breastfeed.Tell your HCP about all the medicines you take, including prescription and over-the-countermedicines, vitamins, and herbal supplements.Nurtec ODT may cause serious side effects including allergic reactions, including trouble breathing and rash. This can happen days after you take Nurtec ODT. Call your HCP or get emergency help right away if you have swelling of the face, mouth, tongue, or throat or trouble breathing. This occurred in less than 1% of patients treated with Nurtec ODT.The most common side effects of Nurtec ODT were nausea (2.7%) and stomach pain/indigestion (2.4%). These are not the only possible side effects of Nurtec ODT. Tell your HCP if you have any side effects.You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.Please click here for full Prescribing Information and Patient Information.American Migraine Foundation. Racial Disparities in Migraine and Headache Care. Available at Racial Disparities in Migraine Care | American Migraine Foundation. Accessed December 6, 2022.PP-NNT-USA-0184. January 2023.